Zhao Han, Lin Li F, Hahn Joshua, Xie Junkai, Holman Harvey F, Yuan Chongli
Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN 47907, USA.
Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47906, USA.
Life (Basel). 2022 Mar 17;12(3):438. doi: 10.3390/life12030438.
Cancer drug resistance is the leading cause of cancer related deaths. The development of drug resistance can be partially contributed to tumor heterogeneity and epigenetic plasticity. However, the detailed molecular mechanism underlying epigenetic modulated drug resistance remains elusive. In this work, we systematically analyzed epigenetic changes in tamoxifen (Tam) responsive and resistant breast cancer cell line MCF7, and adopted a data-driven approach to identify key epigenetic features distinguishing between these two cell types. Significantly, we revealed that DNA methylation and H3K9me3 marks that constitute the heterochromatin are distinctively different between Tam-resistant and -responsive cells. We then performed time-lapse imaging of 5mC and H3K9me3 features using engineered probes. After Tam treatment, we observed a slow transition of MCF7 cells from a drug-responsive to -resistant population based on DNA methylation features. A similar trend was not observed using H3K9me3 probes. Collectively, our results suggest that DNA methylation changes partake in the establishment of Tam-resistant breast cancer cell lines. Instead of global changes in the DNA methylation level, the distribution of DNA methylation features inside the nucleus can be one of the drivers that facilitates the establishment of a drug resistant phenotype in MCF7.
癌症耐药性是癌症相关死亡的主要原因。耐药性的产生部分归因于肿瘤异质性和表观遗传可塑性。然而,表观遗传调控的耐药性背后的详细分子机制仍不清楚。在这项工作中,我们系统地分析了他莫昔芬(Tam)敏感和耐药的乳腺癌细胞系MCF7中的表观遗传变化,并采用数据驱动的方法来识别区分这两种细胞类型的关键表观遗传特征。值得注意的是,我们发现构成异染色质的DNA甲基化和H3K9me3标记在Tam耐药和敏感细胞之间存在显著差异。然后,我们使用工程探针进行了5mC和H3K9me3特征的延时成像。Tam处理后,基于DNA甲基化特征,我们观察到MCF7细胞从药物敏感群体向耐药群体的缓慢转变。使用H3K9me3探针未观察到类似趋势。总体而言,我们的结果表明DNA甲基化变化参与了Tam耐药乳腺癌细胞系的建立。细胞核内DNA甲基化特征的分布而非DNA甲基化水平的全局变化,可能是促进MCF7中耐药表型建立的驱动因素之一。